Overcoming T Cell Exhaustion as a Resistance Mechanism in Immuno-Oncology

Release Date: June 5, 2020
Expiration Date: June 5, 2021

Activity Overview

This continuing medical education (CME) activity is designed to inform healthcare providers who care for patients with cancer using immuno-oncology therapeutics and in whose patients T cell exhaustion may develop as a mechanism of resistance to treatment. This program will cover immune system activation and suppression as mechanisms by which T cell exhaustion develops in cancer, different immunotherapeutic strategies to overcome T cell exhaustion, and investigational approaches for treating cancer in which T cell exhaustion has arisen.

Acknowledgment of Support

This activity is funded by PER^®.

Learning Objectives

Upon successful completion of this educational activity, you should be better prepared to:

• Explain differences between mechanisms of immune activation and suppression in cancer.
• Describe the mechanisms by which T cell exhaustion arises in patients with cancer.
• Assess different immunotherapeutic strategies to overcome T cell exhaustion.
• Evaluate novel and investigational approaches for treating cancer with T cell exhaustion.

This activity was written by PER^® editorial staff under faculty guidance and review. The Q&A portion of the activity was transcribed from a recorded interview with the faculty and edited by faculty and PER^® editorial staff for clarity.

Faculty, Staff, and Planners’ Disclosures

In accordance with ACCME Guidelines, PER^® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.

Faculty

Jason J. Luke, MD
Director of the Cancer Immunotherapeutics Center
Associate Professor of Medicine
UPMC Hillman Cancer Center and University of Pittsburgh School of Medicine
Pittsburgh, PA

Disclosures: Grant/Research Support: (all to institution for clinical trials unless noted) AbbVie, Agios (IIT), Array (IIT), Astellas, Bristol-Myers Squibb, CheckMate (SRA), Compugen, Corvus, EMD Serono, Evelo (SRA), Five Prime, FLX Bio, Genentech, Immatics, Immunocore, Incyte, Leap, MedImmune, Macrogenics, Necktar, Novartis, Palleon (SRA), Merck, Springbank, Tesaro, Tizona, Xencor; Stock/ Shareholder: Actym, Alphamab Oncology, Kanaph, Mavu (now part of AbbVie), Onc.AI, Pyxis, Tempest; Consultant: TTC Oncology; 7 Hills, Actym, Alphamab Oncology, Kanaph, Mavu (now part of AbbVie), Onc.AI, Pyxis, Springbank, Tempest, Consultancy: Abbvie, Akrevia, Algios, Array, Astellas, Bayer, Bristol-Myers Squibb, Eisai, EMD Serono, Ideaya, Incyte, Janssen, Merck, Mersana, Novartis, PTx, RefleXion, Silicon, Tesaro, Vividion; Other Support, Travel: Akrevia, Bayer, Bristol-Myers Squibb, EMD Serono, Incyte, Janssen, Merck, Mersana, Novartis, Pyxis, RefleXion.

The staff Physicians' Education Resource^®, LLC (PER^®) have no relevant financial relationships with commercial interests to disclose.

Off-Label Disclosure and Disclaimer

This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER^® or any company that provided commercial support for this activity.